Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Colonic Neoplasms × cemiplimab × Clear all

Phase

Status

Recruiting 2 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7 Neoplasm Metastasis 2 Lung Neoplasms 2 Vulvar Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Penile Neoplasms 1 Neoplasms 1 Mesothelioma, Malignant 1 Gliosarcoma 1 Glioblastoma 1 Disease Progression 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Carcinoma 1 Advanced Squamous Non-Small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 7 Fluorouracil 4 tislelizumab 3 Irinotecan 3 raltitrexed 2 pembrolizumab 2 Leucovorin 2 Chemotherapy, Adjuvant 2 Capecitabine 2 spartalizumab 1 sintilimab 1 rimegepant sulfate 1 encorafenib 1 cemiplimab 1 XELOX 1 Surgical Procedures, Operative 1 Radiofrequency Ablation 1 Preoperative Exercise 1 Neoadjuvant Therapy 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Mortality 1 Laparoscopy 1 Immune Checkpoint Inhibitors 1 HMPL-013 1 HLX07 1 Genetic Testing 1 Everolimus 1 Drug Therapy 1 Diagnostic Tests, Routine 1 Conversion to Open Surgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07224022 2026-02-04

NACho

Duke University

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡